Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer
The purpose of this study is to assess the effect of pyrotinib
Advanced Breast Cancer
DRUG: pyrotinib
Incidence of first progression with brain metastases, Incidence of first progression with brain metastases, 24 month
ORR without CNS, Baseline to measured stable disease without central nervous system, 24 month|TTBM, Time to brain metastases, 24 month
The purpose of this study is to assess the effect of pyrotinib combined with trastuzumab in the maintenance phase delay/reduction of brain metastases after first-line TH(P) therapy for HER-2-positive advanced breast cancer